Drug Type Chemical drugs |
Synonyms- |
Target |
Mechanism PERK inhibitors(Eukaryotic initiation 2 alpha kinase 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Preclinical | US | Hibercell, Inc.Startup | 19 Oct 2022 |
Diabetes Mellitus | Preclinical | US | 19 Oct 2022 | |
Diabetes Mellitus | Preclinical | CN | 19 Oct 2022 |